Continuous Veno-venous Hemodiafiltration
Conditions
Interventions
Observations:N/A
Sponsors
Public health clinical center of Chengdu
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age>=18 years; 2. Diagnosed with HIV infection and meeting the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of HIV/AIDS (2021 Edition) ; 3. Treatment with bicembrolol anti-HIV for more than 6 months, and HIV-RNA < 50 copies/ml within 6 months; 4. Patients should be in the end-stage renal disease with an estimated glomerular filtration rate (eGFR) of less than 15 mL/min/1.73 m² and stable for at least three months; 5. Hemodialysis twice a week for at least 3 months; 6.Patient or his/her legal guardian has signed informed consent, is willing to participate in the study and complies with the study protocol; 7. Patients are willing to obey medication education and take medication immediately after dialysis on the same day; 8. Patients should have good compliance and be able to cooperate in completing all examinations and follow-up visits during the study.
Exclusion criteria
Exclusion criteria: 1. Patients with comorbidities and complications that may affect drug metabolism and clearance; 2. Patients undergoing peritoneal dialysis or other non-hemodialysis treatment; 3. May use drugs that affect the concentration of the drug in the blood of biconprenol; 4.Patients who are using drugs known to be significantly toxic to the kidneys, or who need to use such drugs during the study period; 5.A history of serious cardiovascular disease, such as myocardial infarction, unstable angina pectoris or severe arrhythmia; 6.Have serious liver disease, such as cirrhosis or chronic active hepatitis, which may affect drug metabolism; 7.Patients who are allergic to the investigational drug or any of its excipients; 8.Pregnant or lactating women; 9.Patients with unstable mental state or cognitive dysfunction, unable to understand the content and requirements of the study; 10.Other situations in which the investigator deems it inappropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| drug concentration in blood; | — |
Secondary
| Measure | Time frame |
|---|---|
| HIV-RNA;CD4+T helper cell subsets;CD4/CD8 ratio;Interleukin-6 (IL-6);Serum Amyloid A(SAA);C-reactive protein(CRP);The urea clearance index(Kt/V);Urea Reduction Ratio(URR);Dialysis dose;Time interval between last medication intake and this dialysis;Adverse Drug Events and Their Incidence Rates; | — |
Countries
China
Contacts
Public ContactLv Fei
Public health clinical center of Chengdu
Outcome results
None listed